STOCK TITAN

Erasca, Inc. - ERAS STOCK NEWS

Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.

Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Their mission, embodied in their name, is to 'erase cancer'. The company's innovative approach aims to not just treat but potentially cure cancer by targeting and shutting down the RAS/MAPK pathway, which plays a crucial role in many types of cancer.

Erasca’s robust clinical pipeline includes promising drug candidates such as Naporafenib, a pan-RAF inhibitor with first-in-class potential targeting NRASm melanoma and RAS Q61X tissue agnostic solid tumors. The company's other notable candidates include ERAS-007, a highly selective oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, which target different nodes of the RAS/MAPK pathway. These efforts are supported by recent collaborations with industry giants like Novartis, who are providing crucial compounds like trametinib (MEKINIST®) for combination trials.

On the financial front, Erasca is well-funded with significant investments from both new and existing investors, having recently raised approximately $45 million in a private placement expected to close in April 2024. As of December 2023, the company reported $322 million in cash, cash equivalents, and marketable securities, ensuring a solid runway into the second half of 2026.

Among their latest achievements, Erasca has received FDA Fast Track Designation (FTD) for Naporafenib in combination with trametinib for advanced NRASm melanoma. This designation facilitates accelerated development and review processes, reflecting the potential of their therapies to address unmet medical needs.

The company’s pivotal Phase 3 SEACRAFT-2 trial for Naporafenib in post-immunotherapy settings for NRASm melanoma is slated to begin in the first half of 2024. Additionally, Erasca has announced exciting new partnerships and pipeline enhancements, including in-licensing two preclinical RAS programs, ERAS-0015 and ERAS-4001, to further solidify their leadership in the precision oncology space.

For more up-to-date information on Erasca, Inc., including their latest financial results and key upcoming milestones, visit their official website or recent press releases.

Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) announces key leadership changes with Lisa Tesvich-Bonora appointed as Chief People Officer and Robert Shoemaker promoted to Senior Vice President of Research. Tesvich-Bonora, with over 20 years of experience in organizational development, will lead initiatives in recruitment and professional development. Shoemaker, one of the company’s founding members, will integrate Discovery Research activities to enhance the development of Erasca’s oncology pipeline. These appointments aim to strengthen Erasca's culture and research capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.95%
Tags
management
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, will participate in the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 PM ET. During the event, CEO Jonathan E. Lim will present an overview of the company and its pipeline. Additionally, Dr. Lim and CFO David M. Chacko will engage in one-on-one investor meetings. A live audio webcast of the presentation will be accessible online, with an archived replay available for 30 days afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
conferences
-
Rhea-AI Summary

Erasca has achieved FDA clearance for its investigational new drug (IND) application for ERAS-801, an EGFR inhibitor, ahead of schedule. This drug is designed for high CNS penetration to treat recurrent glioblastoma multiforme (rGBM) and will enter the THUNDERBBOLT-1 Phase 1 clinical trial in Q1 2022. The collaboration with the Global Coalition for Adaptive Research (GCAR) aims to explore a path for ERAS-801 within the GBM AGILE trial, enhancing the potential for expedited therapy development. With about 125,000 annual rGBM cases worldwide, this advancement addresses a significant unmet need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) has been added to the NASDAQ Biotech Index, effective December 20, 2021. This index tracks biotech and pharmaceutical companies listed on the Nasdaq, and membership requires meeting specific criteria, including market capitalization and trading volume. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers and is backed by experts in precision oncology. This inclusion indicates recognition of the company's growth and stability in the biotechnology sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
none
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a precision oncology company focused on RAS/MAPK pathway-driven cancers, will participate in the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Jonathan E. Lim, M.D., CEO, and David M. Chacko, M.D., CFO, will engage in a "Fireside Chat" at 3:05 PM ET. Investors can register for the live webcast at Evercore.webcasts, with an archived replay available for 30 days on Erasca.com/events.

Erasca aims to develop innovative therapies targeting cancer pathways, leveraging expertise from top pioneers in the field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
conferences
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) reported strong execution in its recent financial results for Q3 2021, highlighting the initiation of two clinical trials for ERAS-007 in lung and gastrointestinal cancers. The company maintained a robust cash position of $487 million, bolstered by a $345 million IPO. Notably, it was named one of Fierce Biotech's "Fierce 15" innovative companies. However, the firm reported a net loss of $46.1 million for the quarter, influenced by significant R&D and G&A expenses, including a $17.5 million donation to the Erasca Foundation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) presented promising preclinical data for ERAS-801, a new EGFR inhibitor with significantly enhanced CNS penetration, at the AACR Conference. ERAS-801 shows a CNS penetration rate four times higher than existing EGFR inhibitors, demonstrating potent efficacy in over 90% of tested EGFR-mutant glioblastoma models. The company plans to submit an IND for refractory glioblastoma in Q1 2022. These advancements highlight ERAS-801's potential to improve outcomes for patients suffering from this aggressive cancer type.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
none
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) announced the dosing of the first patient in the HERKULES-3 trial, a Phase 1b/2 clinical study evaluating ERAS-007, an ERK1/2 inhibitor, in combination with various agents for treating colorectal cancer (CRC). The trial aims to address mutations in BRAF, KRAS, and NRAS, impacting over half of CRC patients. Current therapies show limited effectiveness, with many patients experiencing rapid disease progression. HERKULES-3 will explore the safety and effectiveness of these combinations, potentially leading to significant advancements in CRC treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
Rhea-AI Summary

ERAS-007, a leading ERK1/2 inhibitor, has entered Phase 1b/2 HERKULES-2 trial, focusing on advanced non-small cell lung cancer (NSCLC). Erasca, Inc. has initiated patient dosing to evaluate ERAS-007's effectiveness in combination with osimertinib. This trial aims to address unmet needs, especially for patients resistant to current therapies. The broad applicability of ERAS-007 was reinforced by recent preclinical findings showing strong anti-tumor activity, particularly in tumors with specific mutations. Future expansions will explore additional combinations across various cancer types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags

FAQ

What is the current stock price of Erasca (ERAS)?

The current stock price of Erasca (ERAS) is $2.865 as of November 4, 2024.

What is the market cap of Erasca (ERAS)?

The market cap of Erasca (ERAS) is approximately 795.2M.

What is Erasca, Inc.'s primary focus?

Erasca, Inc. is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

What are the key drugs in Erasca’s pipeline?

Key drugs in Erasca's pipeline include Naporafenib, ERAS-007, and ERAS-601 targeting various nodes of the RAS/MAPK pathway.

What recent achievements has Erasca reported?

Erasca has received FDA Fast Track Designation for Naporafenib in combination with trametinib and announced significant collaborations and financial investments.

How is Erasca funded?

Erasca is funded through a combination of private placements and existing investments, with a strong cash position reported at $322 million as of December 2023.

What partnerships has Erasca entered into?

Erasca has partnered with Novartis, among others, to support clinical development of their drug candidates and has in-licensed two preclinical RAS programs.

What is the SEACRAFT-2 trial?

The SEACRAFT-2 trial is a pivotal Phase 3 study evaluating the efficacy of Naporafenib in combination with trametinib for NRAS-mutant melanoma patients post-immunotherapy.

What does FDA Fast Track Designation mean for Erasca?

FDA Fast Track Designation facilitates accelerated development and review processes for Naporafenib in combination with trametinib, aiming to expedite its availability for patients with advanced NRAS-melanoma.

What financial milestones has Erasca achieved recently?

Recently, Erasca secured approximately $45 million in a private placement and reported a strong cash position to fund operations into 2026.

What is the significance of Erasca's mission statement?

Erasca's mission to 'erase cancer' reflects their dedication to creating transformative oncology therapies aimed at not just treating but potentially curing cancer.

How does Erasca's technology target cancer?

Erasca's technology targets the RAS/MAPK pathway, which is critical in many cancers. Their therapies aim to comprehensively shut down this pathway to treat and potentially cure cancer.

Erasca, Inc.

Nasdaq:ERAS

ERAS Rankings

ERAS Stock Data

795.25M
282.50M
12.4%
77.06%
11.93%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO